<DOC>
	<DOCNO>NCT00796120</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety trabectedin compare standard doxorubicin participant advance translocation-related sarcoma ( cancer connective tissue cell ) ( TRS ) .</brief_summary>
	<brief_title>An Efficacy Safety Study Trabectedin Versus Doxorubicin-Based Chemotherapy Participants With Translocation-Related Sarcomas ( TRS )</brief_title>
	<detailed_description>This randomize ( study drug assign chance ) , multicenter ( one hospital medical school team work medical research study ) , Phase 3 trial evaluate efficacy safety trabectedin compare standard doxorubicin participant advance TRS . Participants randomize 1:1 ratio either 2 treatment group , , trabectedin doxorubicin plus ifosfamide group . Participants trabectedin group receive trabectedin 1.5 milligram per square meter ( mg/m^2 ) give 24-hour continuous intravenous infusion ( fluid medicine deliver vein way needle ) every 3 week doxorubicin plus ifosfamide group participant receive doxorubicin 60 75 mg/m^2 intravenously every 3 week follow ifosfamide 6 9 gram ( g ) /m^2 every 3 week . Participants either treatment arm continue receive therapy absence progressive disease ( PD ) intolerable side effect , participant ' consent withdrawn eligibility criterion continue treatment longer fulfil , concurrent condition precludes continuation treatment . Efficacy assess primarily evaluate progression-free survival ( PFS ) . Participants ' safety monitor throughout trial .</detailed_description>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Trabectedin</mesh_term>
	<mesh_term>Isophosphamide mustard</mesh_term>
	<mesh_term>Ifosfamide</mesh_term>
	<criteria>Pathological diagnosis translocationrelated sarcoma ( TRS ) include follow subtypes : alveolar soft part sarcoma , angiomatoid fibrous histiocytoma , clear cell sarcoma , desmoplastic small round cell tumor , low grade endometrial stromal sarcoma ( prior hormone therapy allow ) , low grade fibromyxoid sarcoma , myxoid chondrosarcoma , myxoid/round cell liposarcoma ( MRCL ) synovial sarcoma Participants must unresectable locally advanced metastatic progressive disease prior enrolment Eastern Cooperative Oncology Group ( ECOG ) Performance Status ( PS ) score 02 Adequate cardiac function , define leave ventricular ejection fraction ( LVEF ) within normal limit accord institutional standard , show echocardiography scintigraphy multiplegated acquisition scan [ MUGA ] Measurable disease define radiological ( computed tomography [ CT ] scan magnetic resonance image [ MRI ] ) Response Evaluation Criteria Solid Tumors ( RECIST v.1.0 ) guideline Known hypersensitivity component intravenous formulation trabectedin comparators Prior chemotherapy treatment irradiation lesion one target lesion available Brain metastasis and/or leptomeningeal metastasis , even treat Pregnant lactate woman men woman reproductive potential use effective contraceptive method History another neoplastic disease ( except basal cell carcinoma cervical carcinoma situ adequately treat ) unless remission five year</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Sarcomas</keyword>
	<keyword>Trabectedin</keyword>
	<keyword>Doxorubicin</keyword>
	<keyword>Ifosfamide</keyword>
	<keyword>YONDELIS</keyword>
</DOC>